Effects of bisphosphonate on bone reaction after placement of titanium implants in tibiae of ovariectomized rats

International Journal of Oral and Maxillofacial Implants

Volumn 18, Issue 1, 2003, Pages 66-74

  Tokugawa, Yuki ^a   Shirota, Tatsuo ^a   Ohno, Kohsuke ^a   Yamaguchi, Akira ^b  

^a SHOWA UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Bisphosphonate; Bone; Dental implants; Estrogen; Ovariectomy; Rat

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ESTRADIOL; ESTROGEN; TITANIUM; INCADRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE MASS; BONE STRUCTURE; CALCIFICATION; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED STUDY; DRUG EFFECT; EVALUATION; FEMALE; MEASUREMENT; METAPHYSIS; MICROSCOPY; MORPHOMETRICS; NONHUMAN; OVARIECTOMY; RAT; STATISTICAL SIGNIFICANCE; TIBIA; TISSUE REACTION; ANIMAL; BONE DENSITY; BONE REGENERATION; DISEASE MODEL; ESTROGEN THERAPY; IMAGE PROCESSING; NONPARAMETRIC TEST; PATHOLOGY; SURFACE PROPERTY; TIME; TOOTH IMPLANTATION; WISTAR RAT;

ANIMALS; BONE DENSITY; BONE REGENERATION; DENTAL IMPLANTS; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; IMAGE PROCESSING, COMPUTER-ASSISTED; OSSEOINTEGRATION; OVARIECTOMY; RATS; RATS, WISTAR; STATISTICS, NONPARAMETRIC; SURFACE PROPERTIES; TIBIA; TIME FACTORS; TITANIUM;

EID: 0038283985     PISSN: 08822786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Riggs BL. Overview of osteoporosis. West J Med 1991;154:63-77.
2. Lindsay R. Prevention of postmenopausal osteoporosis. Obstet Gynecol Clin North Am 1987;14:63-76.
3. Von Wowern N, Klausen B, Kollerup G. Osteoporosis: A risk factor in periodontal disease. J Periodontol 1994;65:1134-1138.
4. Klemetti E, Collin HL, Forss H, Markkanen H, Lassila V. Mineral status of skeleton and advanced periodontal disease. J Clin Periodontol 1994;21:184-188.
5. Kribbs PJ. Comparison of mandibular bone in normal and osteoporotic women. J Prosthet Dent 1990;63:218-222.
6. Fleisch H. Bisphosphonate: Pharmacology and use in the treatment of tumor-induced hypercalcemia and metastatic bone disease. Drugs 1991;42:919-944.
7. Rodan GA, Fleisch H. Bisphosphonate: Mechanisms of action. J Clin Invest 1996;97:2692-2696.
8. Wronski TJ, Dann LM, Scott KS, Crooke LR. Endocrine and pharmacological suppressors of bone turnover protect against osteopenia in ovariectomized rats. Endocrinology 1989;125:810-816.
9. Toolan BC, Shea M, Myers RE, et al. Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats. J Bone Miner Res 1992;7:1399-1406.
10. Lauritzen DB, Balena R, Shea M, et al. Effects of combined prostaglandin and alendronate treatment on the histomorphometry and biomechanical properties of bone in ovariectomized rats. J Bone Miner Res 1993;8:871-879.
11. Ammann P, Rizzoli R, Caverzasio J, Shigematsu T, Slosman D, Bonjour JP. Effects of the bisphosphonate tiludronate on bone reaction. J Bone Miner Res 1993;8:1491-1498.
12. Mosekilde L, Sogaard CH, McOsker JE, Wronski TJ. PTH has more pronounced effect on vertebral bone mass and biomechanical competence than antiresorptive agents (estrogen and bisphosphonate) -assessed in sexually mature, ovariectomized rats. Bone 1994;15:401-408.
13. Søgaard CH, Wronski TJ, McOsker JE, Mosekilde L. The positive effect of parathyroid hormone on femoral neck bone strength in ovariectomized rats in more pronounced than that of estrogen or bisphosphonates. Endocrinology 1994;134:650-657.
14. Qi H, Li M, Wronski TJ. A comparison of the anabolic effects of parathyroid hormone at skeletal site with moderate and severe osteopenia in aged ovariectomized rats. J Bone Mineral Res 1995;10:948-955.
15. Ammann P, Rizzoli R, Meyer JM, Bonjour JP. Bone density and shape as determinants of bone strength in IGF-I and/or pamidronate-treated ovariectomized rats. Osteoporosis Int 1996;6:219-227.
16. Faugere MC, Friedler RM, Bauss F, Malluche HH. A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res 1993;8:1345-1355.
17. Balena R, Toolan BC, Shea M, et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993;92:2577-2586.
18. Fitton A, McTravish D. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991;41:289-318.
19. Cantrill JA, Anderson DC. Treatment of Paget's disease of bone. Clin Endocrinol 1990;32:507-518.
20. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-79.
21. Starck WJ, Epker BN. Failure of osseointegrated dental implants after diphosphonate therapy for Osteoporosis: A case report. Int J Oral Maxillofac Implants 1995;10:74-78.
22. Kudo M, Abe T, Kawamuki K, et al. Effects of YM-175 on experimental hypercalcemia and tumorinduced osteolysis in rats. J Bone Miner Res 1990;5(Suppl):S166.
23. Kawamuki K, Abe T, Kudo M, et al. Effect of YM-175 on bone positively correlates with its concentration in bone. J Bone Miner Res 1990;5(Suppl):S245.
24. Takano Y, Tanizawa T, Mashiba T, Endo N, Nishida S, Takahashi H. Maintaining bone mass by bisphosphonate incadronate disodium (YM-175) sequential treatment after discontinuation of intermittent human parathyroid hormone (1-34) administration in ovariectomized rats. J Bone Miner Res 1996;11:169-177.
25. Motoie H, Nakamura T, O'uchi N, et al. Effects of the bisphosphonate YM- 175 on bone mineral density, strength, structure, and turnover in ovariectomized beagles on concomitant dietary calcium restriction. J Bone Miner Res 1995;10:910-920.
26. Takeuchi M, Sakamoto S, Yoshida M, Abe T, Isomura Y. Studies on novel bone resorption inhibitors. I. Synthesis and pharmacological activitis of aminomethylenebisphosphonate derivatives. Chem Pharmaceut Bull (Tokyo) 1993;41:688-693.
27. Nyman MT, Gao T, Lindholm TC, Lindholm TS. Healing of a tibial double osteotomy is modified by clodronate administration. Arch Orthop Trauma Surg 1996;115:111-114.
28. Li J, Mori S, Kaji Y, Mashiba T, Kawanishi J, Norimastu H. Effects of bisphosphonate (incadronate) on fracture healing of long bones in rats. J Bone Miner Res 1999;14:969-979.
29. Peter CP, Cook WO, Nunamaker DM, Provost MT, Seedor JG, Roda GA. Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 1996;14:74-79.
30. Motohashi M, Shirota T, Tokugawa Y, Ohno K, Michi K, Yamaguchi A. Bone reactions around hydroxyapatite-coated implants in ovariectomized rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;87:145-152.
31. Pan J, Shirota T, Ohno K, Michi K. Effects of ovariectomy on bone remodeling adjacent to hydroxyapatite-coated implants in the tibia of mature rats. J Oral Maxillofac Surg 2000;58:877-882.
32. Aro HT, Wippermann BW, Hodgson SF, Chao KY. Internal remodeling of periosteal new bone during fracture healing. J Orthop Res 1990;8:238-246.
33. Frost HM. The biology of fracture healing. An overview for clinicians. Part I. Clin Orthop Res 1989;248:283-293.
34. Hiraga T, Tanaka S, Yamamoto M, Nakajima T, Ozawa H. Inhibitory effects of bisphosphonate (YM-175) on bone resorption induced by a metastatic bone tumor. Bone 1996;18:1-7.